Application of lactucin in preparation of product for promoting skin aging resistance and skin repair

Abstract

The invention relates to an application of lactucin in preparation of a product for promoting skin aging resistance and skin repair. A large number of experiments prove that the lactucin can promote skin aging resistance and skin repair and has good safety, and the specific expressions are as follows: the lactucin can activate the expression of SIRT1 protein and is superior to that of the existing activator resveratrol; the lactucin can obviously inhibit the reduction of the content of various collagens in skin keratinocytes caused by UV light aging stimulation; the lactucin can promote the healing ability of cell scratches. In conclusion, the lactucin has great clinical application prospect and value in preparation of the product for promoting skin aging resistance and repair.

Description

Technical Field

[0001] The present application relates to the field of biomedical technologies, and particularly to the application of lactucopicrin in the preparation of products for promoting skin anti-aging and skin repair. Background Art

[0002] Skin aging is a complex process, generally referring to the senescent damage of skin functions, resulting in the decline of the skin's protective ability, regulatory ability, etc. for the body, so that the skin cannot adapt to the changes in the internal and external environments, and changes occur in the overall appearance such as color, luster, shape, texture, etc. Macroscopically, skin aging is manifested as fine lines, reduced elasticity, orange peel-like changes or skin dullness, as well as a decrease in the thickness of the epidermis and dermis. At the microscopic level, typical skin aging characteristics include epidermal atrophy, reduced mitotic rate of basal keratinocytes, decreased proliferation ability and cell senescence, as well as atrophy of the extracellular matrix of dermal cells and changes in the physiological properties of connective tissues.

[0003] The skin is the first line of defense of the human body, which can resist external force extrusion and impact, prevent the invasion of microorganisms, chemical substances and ultraviolet rays, and protect internal tissues from damage. However, with the growth of age and the influence of external factors such as ultraviolet (UV) irradiation, collagen in the human body gradually loses, resulting in the loss of skin elasticity and firmness, and problems such as wrinkles and sagging appear. Therefore, the reduction of collagen is a significant feature in the process of skin aging. Summary of the Invention

[0004] Based on this, the purpose of the present application includes providing the application of lactucopicrin in the preparation of products for promoting skin anti-aging and skin repair.

[0005] The technical solution of the present application is as follows:

[0006] The present invention provides the application of lactucopicrin in the preparation of products for promoting skin anti-aging and skin repair.

[0007] In one embodiment, the product includes cosmetics, food or drugs.

[0008] In one embodiment, the cosmetics include one or more of lotion, cream, emulsion, essence, facial mask and eye cream.

[0009] In one embodiment, the food includes one or more of functional foods, beverages, health products and nutritional supplements.

[0010] In one embodiment, the dosage form of the drug includes oral solution, liquid suspension, powder, tablet, capsule, powder, mixture, pill, granule, syrup, plaster, suppository, aerosol, ointment or injection.

[0011] In one embodiment, the product further comprises adjuvants; and / or

[0012] The administration methods of the product include oral administration and / or external application.

[0013] In one embodiment, the external application includes topical surface administration and / or systemic transdermal administration.

[0014] In one embodiment, the promotion of skin anti-aging includes one or more of improving skin photoaging, improving wrinkles, improving age spots, and improving skin laxity.

[0015] In one embodiment, the skin repair refers to activating the expression of SIRT1; and / or

[0016] The skin repair refers to promoting the expression of collagen; and / or

[0017] The skin repair refers to promoting cell healing.

[0018] In one embodiment, the collagen is one or both of Collagen I and Collagen III.

[0019] Compared with the prior art, the present application has the following beneficial effects:

[0020] The inventors of the present application have confirmed through a large number of experiments that lactupicrin can promote skin anti-aging and skin repair, and has good safety. Specifically, lactupicrin can activate the expression of SIRT1 protein, and is superior to the existing activator resveratrol; lactupicrin can significantly inhibit the decrease in the content of various collagens in human skin keratinocytes caused by UV photoaging stimulation; lactupicrin can promote the healing ability of cell scratches. In summary, lactupicrin has great clinical application prospects and value in the preparation of products for promoting skin anti-aging and repair. Description of the Drawings

[0021] In order to more clearly illustrate the specific embodiments of the present application or the technical solutions in the prior art, the following will briefly introduce the drawings required for the description of the specific embodiments or the prior art. Obviously, the drawings in the following description are some embodiments of the present application. For those of ordinary skill in the art, without creative efforts, other drawings can also be obtained based on these drawings.

[0022] Figure 1 It is a graph showing the toxicity test results of Lactupicrin on immortalized human skin keratinocytes in Example 1.

[0023] Figure 2Graph showing the activation effect of Lactupicrin on SIRT1 protein in Example 1.

[0024] Figure 3 Graph showing the promoting effect of Lactupicrin on the expression of various collagens in Example 1.

[0025] Figure 4 Graph showing the promoting effect of Lactupicrin on the healing of scratched human skin immortalized keratinocytes in Example 1. Detailed implementation manners

[0026] To make the above objects, features, and advantages of the present application more apparent and understandable, the following provides a detailed description of the specific implementation manners of the present application. Many specific details are set forth in the following description to facilitate a full understanding of the present application. However, the present application can be implemented in many other ways different from those described herein, and those skilled in the art can make similar improvements without departing from the connotation of the present application. Therefore, the present application is not limited by the specific embodiments disclosed below.

[0027] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the technical field to which this application belongs. The terms used in the description of this application herein are only for the purpose of describing specific embodiments and are not intended to limit this application.

[0028] Unless otherwise stated or there is a contradiction, the terms or phrases used herein have the following meanings:

[0029] As used herein, "pharmaceutically acceptable" refers to those ligands, materials, compositions, and / or dosage forms that are suitable for administration to a patient within the scope of reasonable medical judgment and are commensurate with a reasonable benefit / risk ratio.

[0030] As used herein, "pharmaceutically acceptable salts" refer to salts formed from any of the compounds of the indicated structures with acids or bases that are suitable for use as pharmaceuticals. Pharmaceutically acceptable salts include inorganic salts and organic salts. Among them, one class of salts are the salts formed by the compounds of the present application with acids. Acids suitable for forming salts include, but are not limited to: inorganic acids such as hydrochloric acid, hydrobromic acid, hydrofluoric acid, sulfuric acid, nitric acid, phosphoric acid; organic acids such as formic acid, acetic acid, trifluoroacetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, picric acid, benzoic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, benzenesulfonic acid, naphthalenesulfonic acid; and amino acids such as proline, phenylalanine, aspartic acid, glutamic acid. Another class of salts are the salts formed by the compounds of the present application with bases. Bases suitable for forming salts include, but are not limited to: alkali metal salts (such as sodium salts or potassium salts), alkaline earth metal salts (such as magnesium salts or calcium salts), ammonium salts (such as lower alkanolammonium salts and other pharmaceutically acceptable amine salts), such as methylamine salts, ethylamine salts, propylamine salts, dimethylamine salts, trimethylamine salts, diethylamine salts, triethylamine salts, tert-butylamine salts, ethylenediamine salts, hydroxyethylamine salts, dihydroxyethylamine salts, trihydroxyethylamine salts, and amine salts formed from morpholine, piperazine, and lysine, respectively.

[0031] As used herein, "pharmaceutically acceptable carrier" refers to a pharmaceutically acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, excipient, solvent, or encapsulating material. As used herein, the phrase "pharmaceutically acceptable carrier" includes buffers, sterile water for injection, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are compatible with the administration of the drug. Each carrier must be "pharmaceutically acceptable" in the sense of being compatible with the other ingredients in the formulation and not harmful to the patient. Suitable examples include, but are not limited to: (1) sugars, such as lactose, glucose, and sucrose; (2) starches, such as corn starch, potato starch, and substituted or unsubstituted β-cyclodextrin; (3) cellulose and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose, and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository wax; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerol, sorbitol, mannitol, and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffers, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethanol; (20) phosphate buffer; (21) other non-toxic compatible substances used in pharmaceutical formulations.

[0032] As used herein, "one or more" refers to any one, any two, or any two or more of the listed items.

[0033] In this text, the optional scope of "and / or", "or / and", and "and / or" includes any one of two or more related listed items, and also includes any and all combinations of the related listed items. The said any and all combinations include any two related listed items, any more related listed items, or the combination of all related listed items. (It should be noted that when at least three items are connected by at least two conjunctive combinations selected from "and / or", "or / and", and "and / or", it should be understood that in this application, this technical solution undoubtedly includes the technical solution connected by "logical AND", and also undoubtedly includes the technical solution connected by "logical OR". For example, "A and / or B" includes three parallel solutions: A, B, and A + B. Another example, the technical solution of "A, and / or, B, and / or, C, and / or, D" includes any one of A, B, C, and D (that is, the technical solution connected by "logical OR"), and also includes any and all combinations of A, B, C, and D, that is, it includes the combination of any two or any three of A, B, C, and D, and also includes the four-item combination of A, B, C, and D (that is, the technical solution connected by "logical AND").)

[0034] In this text, words such as "further", "even further", and "especially" are used for descriptive purposes, indicating differences in content, but should not be construed as limiting the scope of protection of this application.

[0035] In this application, when it comes to numerical ranges, unless otherwise specified, the above numerical ranges are considered continuous and include the minimum value and the maximum value of the range, as well as every value between such minimum and maximum values. Further, when the range refers to integers, it includes every integer between the minimum and maximum values of the range. In addition, when multiple ranges are provided to describe features or characteristics, these ranges can be combined. In other words, unless otherwise specified, all ranges disclosed herein should be understood to include any and all sub-ranges subsumed therein.

[0036] This text only specifically discloses some numerical ranges. However, any lower limit can be combined with any upper limit to form a range not explicitly recorded; and any lower limit can be combined with other lower limits to form a range not explicitly recorded. Similarly, any upper limit can be combined with any other upper limit to form a range not explicitly recorded. In addition, each individually disclosed point or single numerical value itself can be used as a lower limit or an upper limit and combined with any other point or single numerical value or combined with other lower limits or upper limits to form a range not explicitly recorded. The use of numerical ranges represented by endpoints includes all numbers within the range and any range within the range. For example, 1 to 5 includes 1, 1.1, 1.3, 1.5, 2, 2.75, 3, 3.80, 4, and 5, etc.

[0037] In this application, unless otherwise specified, the percentage content for solid-liquid mixing and solid-solid mixing refers to the mass percentage, and for liquid-liquid mixing, it refers to the volume percentage.

[0038] In this application, unless otherwise specified, the percentage concentration refers to the final concentration. The final concentration refers to the proportion of the added component in the system after adding this component.

[0039] In this application, unless otherwise specified, the temperature parameter allows both constant temperature treatment and treatment within a certain temperature range. The constant temperature treatment allows the temperature to fluctuate within the accuracy range controlled by the instrument. It is allowed to fluctuate within a range such as ±5°C, ±2°C, ±1°C, ±0.5°C, ±0.4°C, ±0.3°C, ±0.2°C, ±0.1°C. Normal temperature or room temperature in this application refers to no temperature control operation, generally referring to 4°C to 35°C, preferably 20 ± 5°C.

[0040] In this application, among the technical features described in an open-ended manner, it includes a closed technical solution composed of the listed features, and also includes an open technical solution containing the listed features.

[0041] Silent information regulator 1 (SIRT1) is a NAD + -dependent deacetylase and is an important member of the sirtuins family, existing in eukaryotes and prokaryotes. The sirtuins protein family plays important roles in different cellular processes such as apoptosis, mitochondrial biogenesis, lipid metabolism, fatty acid oxidation, cellular stress response, insulin secretion, and aging. At the cellular level, SIRT1 can interact with a variety of proteins. It participates in regulating the apoptosis and aging processes of cells under stress conditions and can enhance the cell activity and the ability of self-repair and survival. And SIRT1 can inhibit the activity pathway of cyclooxygenase (COX), reduce the inflammatory response, and play a certain protective role in nerve injury; it can also improve the aging of human skin fibroblasts caused by ultraviolet irradiation and prevent photoaging caused by UV by inhibiting the activity of matrix metalloproteinases and reducing collagen degradation.

[0042] Lactupicrin is a unique bitter sesquiterpene lactone with pharmacological activities such as antimalarial, anticancer, analgesic, and sedative effects. Its chemical formula is C 23 H 22 O7, and the structural formula is as follows: Studies have shown that Lactupicrin has the effect of protecting against atherosclerosis; in LPS-stimulated mouse bone marrow-derived macrophages, lactucopicrin inhibits the activation of NF-κB and simultaneously inhibits the expression of IL-1β, IL-6, and tumor necrosis factor-α; in apolipoprotein E-deficient mice on a high-fat diet, lactucopicrin dose-dependently reduces plaque area, inhibits the accumulation of plaque macrophages, attenuates the activation of NF-κB in plaque macrophages, and reduces the inflammatory burden in plaques and serum. However, there is currently no study showing that Lactupicrin can affect the expression of the aging-related protein SIRT1 and its function in skin protection.

[0043] Based on this, the present invention provides the use of lactucopicrin in the preparation of products for promoting skin anti-aging and skin repair.

[0044] In some examples, the product further comprises excipients.

[0045] In some examples, the administration methods of the product include oral administration and / or topical administration.

[0046] In some examples, the topical administration includes local surface administration and / or systemic transdermal administration.

[0047] In some examples, the product includes cosmetics, foods, or drugs.

[0048] In some examples, the cosmetics include one or more of lotion, cream, emulsion, essence, facial mask, and eye cream.

[0049] In some examples, the foods include one or more of functional foods, beverages, health products, and nutritional supplements.

[0050] In some examples, the drug includes the active ingredient lactucopicrin and pharmaceutically acceptable excipients. Further, the pharmaceutically acceptable excipients include, but are not limited to, pharmaceutically acceptable salts, diluents, wetting agents, binders, disintegrants, lubricants, color, flavor, and odor regulators, solvents, solubilizers, cosolvents, emulsifiers, antioxidants, metal chelating agents, inert gases, preservatives, local anesthetics, pH regulators, isotonic or isosmotic regulators, etc.

[0051] In some examples, the dosage forms of the drug include oral solutions, liquid suspensions, powders, tablets, capsules, powders, mixtures, pills, granules, syrups, patches, suppositories, aerosols, ointments, or injections. It can be understood that the drugs of the present application can be prepared into suitable clinical dosage forms by adding different pharmaceutically acceptable excipients, and these clinical dosage forms include, but are not limited to, the dosage forms described herein.

[0052] In some of these examples, the drug can be administered via a suitable route of administration according to clinical needs. Understandably, the routes of administration of the drug include intravenous injection, intraperitoneal injection, intramuscular injection, subcutaneous injection, oral administration, sublingual administration, nasal administration, or transdermal administration.

[0053] In some of these examples, the promotion of skin anti-aging includes one or more of improving skin photoaging, improving wrinkles, improving age spots, and improving skin laxity.

[0054] In some of these examples, the skin repair refers to activating the expression of SIRT1. Specifically, lactucopicrin can be used as a deacetylase SIRT1 activator to increase the activity of SIRT1 protein, and experiments have shown that lactucopicrin can activate the expression of SIRT1 protein, which is superior to the recognized activator resveratrol.

[0055] In some of these examples, the skin repair refers to promoting the expression of collagen. Specifically, experiments have shown that Lactupicrin can significantly inhibit the decrease in the content of various collagens in human skin keratinocytes stimulated by UV photoaging.

[0056] In some of these examples, the skin repair refers to promoting cell healing. Specifically, experiments have shown that lactucopicrin can promote the healing ability of cell scratches, promote skin wound healing, and accelerate repair.

[0057] In some of these examples, the collagen is one or both of Collagen I and Collagen III.

[0058] In summary, the present application discloses the use of a novel SIRT1 activator in resisting skin photoaging. The compound consists of lactucopicrin. This compound can simultaneously activate the aging-related protein SIRT1, promote the expression of various types of collagens in immortalized human skin keratinocytes, promote the healing ability of skin cells, and has no obvious side effects. The compound of the present invention can be used for the preparation of applications related to skin anti-aging.

[0059] The following is a further description in combination with specific examples. For the raw materials involved in the following specific examples, unless otherwise specified, they can all be obtained commercially; for the instruments used, unless otherwise specified, they can all be obtained commercially; for the processes involved, unless otherwise specified, they are all conventional selections of those skilled in the art.

[0060] Some of the raw materials used in the examples are as follows:

[0061] Immortalized human skin keratinocytes (HaCaT) were purchased from Zhejiang Meisen Cell Technology Co., Ltd.;

[0062] Resveratrol and Lactupicrin were purchased from MedChemExpress.

[0063] The positive control compound resveratrol used in this article is a polyphenolic compound, also known as piceatannol, which is an antitoxin produced by many plants when stimulated. Its chemical formula is C 14 H 12 O3. Resveratrol can scavenge and inhibit the generation of free radicals, regulate the activities related to antioxidant enzymes, inhibit the aging caused by lipid peroxides produced by metabolites, solve the problem of skin damage from the root, resist skin aging, and achieve the effect of reverse growth. Resveratrol can inhibit the activities of melanocytes and tyrosinase, thereby reducing melanin formation and achieving the whitening effect. Resveratrol can activate acetylase and is a strong inducer of SIRT1, which can increase the expression of SIRT1 in organs and tissues such as the brain, heart, intestine, kidney, muscle, and fat. Resveratrol can promote the proliferation of collagen, fibroblasts, and epidermal keratinocytes, thereby increasing skin elasticity and achieving anti-aging. Research shows that resveratrol is a substance that can support wound healing, eliminate excessive scars, and prevent skin photoaging.

[0064] The following are specific examples.

[0065] Example 1

[0066] I. Cell culture: Human immortalized keratinocytes (HaCaT) were used in the experiment. They were fully mixed with DMEM complete medium and inoculated at 6×10 5 cells in a 6-cm cell culture dish and placed in a cell culture incubator at 37°C, 5% CO2, and saturated humidity for culture. The cells adhered and grew. When they grew to cover 80% of the bottom area of the culture dish, subculture began. When subculturing, the original culture medium was aspirated, washed twice with PBS, digested with 0.25% trypsin, and left to stand in the cell culture incubator for 7 minutes until the cells shrank, became round, and gradually detached from the culture flask. Then, a complete medium with twice the volume of trypsin was added to stop digestion. The cell suspension was collected, centrifuged, resuspended with an appropriate amount of complete medium, counted, and cells at a certain concentration were transferred to a new culture dish, and 10 mL of culture medium was added, and the cells were mixed evenly and spread in the dish.

[0067] II. Cell drug treatment: When the cells grew to the logarithmic growth phase, they were digested and counted, and inoculated at 6×10 5 cells in a 6-cm culture dish (5×10 5 cells in a 6-well plate; 1×10 4Placed in a 96-well plate, and cultured in a CO2 incubator at 37°C, 5% CO2, and saturated humidity for 24 h. After the cells adhered, the model groups (UV group, ultraviolet group) and the drug treatment groups were irradiated with UVA 95% + UVB 5% in an ultraviolet aging chamber to simulate natural light ultraviolet for 90 min, and then the culture medium was changed. The model groups were added with an equal amount of complete medium, and the drug treatment groups were added with the complete medium containing the corresponding concentrations of each drug, and then continued to be placed in the cell culture incubator for the required time for subsequent experimental detection. The treatment method for the control group was: without ultraviolet irradiation and drug treatment, similar to the operation after 90 minutes of ultraviolet irradiation in the model group, and the drug-free medium was replaced synchronously.

[0068] The drugs used in the drug treatment groups included resveratrol solution and Lactupicrin solution. The preparation methods were as follows: Resveratrol and Lactupicrin were respectively dissolved in dimethyl sulfoxide (DMSO) to prepare stock solutions of 10 mM, and diluted according to their respective working concentrations in the experiment.

[0069] III. Safety detection of drugs: When the cell density of the cells treated with drugs in the 96-well plate reached about 80% of the bottom area of the culture dish, the original culture medium after drug treatment was replaced according to the ratio of CCK-8 reagent and cell culture medium (1:10), and continued to be cultured in a CO2 incubator at 37°C, 5% CO2, and saturated humidity for 2 h. The absorbance was detected at a wavelength of 450 nm, and the effect of the drug on the cell survival rate was calculated to judge the toxicity of the drug. The results are as Figure 1 shown. The results showed that Lactupicrin had no significant effect on cell viability within the concentration range of 0 - 3.5 μM, which was regarded as the safe concentration range.

[0070] IV. Detection of the effects of drugs on the expression of senescence-related protein SIRT1 and various types of collagen: After cell modeling by UV stimulation, the drug treatment groups were respectively added with Lactupicrin (1 μM) and resveratrol (1 μM) to treat human immortalized keratinocytes for 24 h. Then the cells were collected and proteins were extracted for WB (Western Blot) experiments. In this application, SIRT1 and various types of collagen Collagen Ⅰ and Collagen Ⅲ were detected. By comparing with the control group, it could be judged whether the model group was successfully established. If the expressions of SIRT1 and collagen in the model group were significantly decreased compared with the control group, the model was successfully established, otherwise it was not. At the same time, the expressions of SIRT1 and collagen in the drug treatment groups were compared with those in the model group to judge the activation effect of the drug on SIRT1 and the promotion of collagen expression.

[0071] The results are as Figures 2 - 3As shown, the results indicate that Lactupicrin can significantly activate the expression of SIRT1 and has a significant promoting effect on the synthesis of both Collagen Ⅰ and Collagen Ⅲ. At the same time, compared with the positive control group of resveratrol at the same concentration, Lactupicrin has a stronger activating effect on SIRT1 and a stronger promoting effect on collagen expression.

[0072] V. Detection of the effect of the drug on the wound healing ability of cell scratches: Cells were seeded in 6-well plates (5×10 5 cells / well) and cultured into a monolayer. When the cell confluence reached 100%, the medium was changed after simulating natural light ultraviolet irradiation with a UVA95%+UVB5% ultraviolet aging box for 90 min. A 200 μL sterile pipette tip was used to scratch the surface of the monolayer cells, and the floating cells remaining in the wells were washed with PBS. The area of the scratched area was photographed and recorded under a microscope. In the drug treatment groups, Lactupicrin (1 μM) and resveratrol (1 μM) were added respectively, and human immortalized keratinocytes were cultured with a cell culture medium without fetal bovine serum for 24 h. After the culture was completed, the area of the scratched area at 24 h was photographed and recorded.

[0073] The results are as Figure 4 shown. The results indicate that after UV irradiation, the wound healing ability of cell scratches is significantly reduced, while both Lactupicrin and resveratrol can promote the wound healing ability of cell scratches under UV irradiation, and the healing effect of Lactupicrin is higher than that of the positive control group of resveratrol.

[0074] In summary, the following conclusions can be obtained through the efficacy experiments:

[0075] (1) It is first discovered in this application that the compound Lactupicrin can activate the expression of SIRT1 protein and is superior to the well-known activator resveratrol;

[0076] (2) It is first discovered in this application that the compound Lactupicrin can significantly inhibit the decrease in the content of various collagens in skin keratinocytes caused by UV photoaging stimulation;

[0077] (3) It is first discovered in this application that the compound Lactupicrin can promote the wound healing ability of cell scratches.

[0078] The technical features of the above-described embodiments can be combined arbitrarily. For the sake of brevity of description, not all possible combinations of the technical features in the above embodiments are described. However, as long as there is no contradiction in the combination of these technical features, it should be considered as the scope recorded in this specification.

[0079] The above-described embodiments merely represent several implementation manners of the present application. The description is relatively specific and detailed, but it should not be construed as a limitation on the scope of the patent application. It should be noted that for those of ordinary skill in the art, without departing from the concept of the present application, several modifications and improvements can still be made, and these all fall within the protection scope of the present application. Therefore, the protection scope of the patent of the present application shall be subject to the appended claims, and the specification can be used to explain the content of the claims.

Claims

1. Application of lactucin in the preparation of products promoting skin anti-aging and skin repair.

2. The use according to claim 1, characterized in that: The product includes a cosmetic, a food or a medicine.

3. The use according to claim 2, characterized in that: The cosmetics include one or more of lotion, cream, emulsion, essence, facial mask and eye cream.

4. The use according to claim 2, characterized in that: The food includes one or more of functional food, beverage, health product and nutritional supplement.

5. The use according to claim 2, characterized in that: The dosage form of the drug includes oral solution, liquid suspension, powder, tablet, capsule, powder, mixture, pill, granule, syrup, plaster, suppository, aerosol, ointment or injection.

6. The use according to any one of claims 1 to 5, characterized in that: The product also includes excipients; and / or The administration of the product includes oral administration and / or topical administration.

7. The use according to claim 6, characterized in that: The external application includes local administration and / or systemic transdermal administration.

8. The use according to any one of claims 1 to 5, characterized in that: The promoting skin anti-aging includes one or more of improving skin photoaging, improving wrinkles, improving pigmentation and improving skin sagging.

9. The use according to any one of claims 1 to 5, characterized in that: The skin repair refers to activating the expression of SIRT1; and / or The skin repair refers to promoting the expression of collagen; and / or The skin repair refers to promoting cell healing.

10. The use according to claim 9, characterized in that: The collagen is one or both of Collagen I and Collagen III.

Images